文献速递遗传性与小管间质肾病慢性肾脏病

遗传背景显著影响Pkd1RC/RC小鼠模型肾脏囊性疾病严重程度

The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease.
PubMed 文献 · Kidney Int · 2021-03-09

该研究将Pkd1RC/RC小鼠分别近交至BALB/cJ和129S6/SvEvTac背景,并与C57BL/6J杂交获得F1代,发现BC和129背景的囊肿病变比B6更严重且进展更快,F1代疾病严重程度居中,托伐普坦临床前测试采用F1(129/B6)-Pkd1RC/RC品系。

要点

  • 不同遗传背景的Pkd1RC/RC小鼠囊肿严重程度和进展速度差异显著。
  • F1(129/B6)-Pkd1RC/RC品系疾病进展适中且同基因变异性有限,适合临床前测试。
  • MRI可用于随机分组并提供总肾脏体积终点,补充传统数据。

核心结论

  • 遗传背景可显著影响Pkd1RC/RC小鼠肾脏囊性疾病的严重程度和进展速度。
  • F1(129/B6)-Pkd1RC/RC品系具有中等进展性疾病和有限的同基因变异性,适合作为临床前测试的标准化模型。

研究设计与样本

  • 将Pkd1RC/RC小鼠近交至BALB/cJ或129S6/SvEvTac背景,并与C57BL/6J杂交获得F1代(BC/B6或129/B6)。
  • 评估1至9月龄的囊肿疾病严重程度、肾功能、纤维化及胆道发育异常。
  • 使用托伐普坦作为阳性对照,在F1(129/B6)-Pkd1RC/RC品系中进行临床前测试,并利用MRI随机分组和提供总肾脏体积终点。

主要发现

  • 在1月龄时,BC和129背景的Pkd1RC/RC小鼠囊肿疾病比B6背景更严重,并持续更快速进展至6-9月龄。
  • 此后疾病扩展阶段进入平台期或下降,同时伴有纤维化增加和肾功能明显下降。
  • 疾病严重程度越高,动物间和肾脏间变异性越大,尤其在129品系中。
  • 两种F1组合的疾病严重程度居中,更接近B6背景,但从1月龄开始进展。
  • 所有背景均可见轻度胆道发育异常和从近端小管到集合管囊肿的早期转换。

临床怎么用

  • 选择Pkd1RC/RC小鼠模型时需考虑遗传背景对疾病表型的影响。
  • F1(129/B6)-Pkd1RC/RC品系可用于ADPKD临床前药物测试,以评估疗效。
  • MRI可用于随机分组和提供总肾脏体积终点,补充传统数据。

局限性

  • 研究仅涉及三种近交背景及其F1代,结论外推至其他遗传背景需谨慎。
  • 疾病进展至6-9月龄后出现平台期/下降,可能限制长期干预研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease (ADPKD), primarily due to PKD1 or PKD2 mutations, causes progressive kidney cyst development and kidney failure. There is significant intrafamilial variability likely due to the genetic background and environmental/lifestyle factors; variability that can be modeled in PKD mice. Here, we characterized mice homozygous for the PKD1 hypomorphic allele, p.Arg3277Cys (Pkd1RC/RC), inbred into the BALB/cJ (BC) or the 129S6/SvEvTac (129) strains, plus F1 progeny bred with the previously characterized C57BL/6J (B6) model; F1(BC/B6) or F1(129/B6). By one-month cystic disease in both the BC and 129 Pkd1RC/RC mice was more severe than in B6 and continued with more rapid progression to six to nine months. Thereafter, the expansive disease stage plateaued/declined, coinciding with increased fibrosis and a clear decline in kidney function. Greater severity correlated with more inter-animal and inter-kidney disease variability, especially in the 129-line. Both F1 combinations had intermediate disease severity, more similar to B6 but progressive from one-month of age. Mild biliary dysgenesis, and an early switch from proximal tubule to collecting duct cysts, was seen in all backgrounds. Preclinical testing with a positive control, tolvaptan, employed the F1(129/B6)-Pkd1RC/RC line, which has moderately progressive disease and limited isogenic variability. Magnetic resonance imaging was utilized to randomize animals and provide total kidney volume endpoints; complementing more traditional data. Thus, we show how genetic background can tailor the Pkd1RC/RC model to address different aspects of pathogenesis and disease modification, and describe a possible standardized protocol for preclinical testing.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Arroyo J, Escobar-Zarate D, Wells HH, et al. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease. Kidney Int. 2021. PMID: 33705824. doi:10.1016/j.kint.2021.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。